JP6880871B2 - Aerosol agent - Google Patents
Aerosol agent Download PDFInfo
- Publication number
- JP6880871B2 JP6880871B2 JP2017052720A JP2017052720A JP6880871B2 JP 6880871 B2 JP6880871 B2 JP 6880871B2 JP 2017052720 A JP2017052720 A JP 2017052720A JP 2017052720 A JP2017052720 A JP 2017052720A JP 6880871 B2 JP6880871 B2 JP 6880871B2
- Authority
- JP
- Japan
- Prior art keywords
- minoxidil
- undiluted solution
- aerosol agent
- transparent glass
- dimethyl ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000443 aerosol Substances 0.000 title claims description 52
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 63
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 53
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 37
- 229960003632 minoxidil Drugs 0.000 claims description 37
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 34
- 239000011550 stock solution Substances 0.000 claims description 34
- 239000003380 propellant Substances 0.000 claims description 29
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 20
- 235000014655 lactic acid Nutrition 0.000 claims description 17
- 239000004310 lactic acid Substances 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000011521 glass Substances 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 20
- 239000013078 crystal Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 239000003915 liquefied petroleum gas Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- -1 surprisingly Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000005028 tinplate Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、ミノキシジルを含有する経時的に安定なエアゾール剤に関する。更に詳細には、低温保管時に析出物を生じないミノキシジル含有エアゾール剤に関する。 The present invention relates to a time-stable aerosol agent containing minoxidil. More specifically, the present invention relates to a minoxidil-containing aerosol agent that does not form a precipitate when stored at a low temperature.
ミノキシジルは化学名を6−(1−ピペリジニル)−2,4−ピリミジンジアミン−3−オキサイドと称し、育毛剤としての適応が知られており(特許文献1)、優れた育毛・発毛効果を発揮する薬剤として多数の報告がある。 Minoxidil has a chemical name of 6- (1-piperidinyl) -2,4-pyrimidinediamine-3-oxide and is known to be applied as a hair restorer (Patent Document 1), and has excellent hair growth and hair growth effects. There are many reports as a drug to exert.
ミノキシジルを頭皮に適用する形態として、主に液剤やローション剤が知られている。ミノキシジルは、溶液中で低温状態に長時間保存すると結晶が析出されるという現象が生じることが知られており、結晶析出を抑制するための技術(特許文献2〜4)が報告されている。
一方、別の形態としてエアゾール剤も知られている。噴射剤の気化により冷感を得られることや、優れた遮光性により成分の保存安定性に優れるといった特徴を有する剤形である。特定の噴射性状にすることによりミノキシジルを頭皮に確実に到達させるエアゾール剤に関する技術が開示されている(特許文献5)。
Liquid agents and lotions are mainly known as forms for applying minoxidil to the scalp. Minoxidil is known to cause a phenomenon in which crystals are precipitated when stored in a solution at a low temperature for a long time, and techniques for suppressing crystal precipitation (Patent Documents 2 to 4) have been reported.
On the other hand, an aerosol agent is also known as another form. It is a dosage form that has the characteristics that a cooling sensation can be obtained by vaporizing the propellant and that the storage stability of the components is excellent due to the excellent light-shielding property. A technique relating to an aerosol agent that ensures that minoxidil reaches the scalp by making it have a specific jetting property is disclosed (Patent Document 5).
本発明者らは、低温でも結晶析出の生じないミノキシジル含有エアゾール剤を提供するにあたり、低温で結晶析出の生じないミノキシジル含有液剤を調製してこれを原液とし、それに噴射剤を加えてエアゾール剤の製造を試みた。より詳細には、ミノキシジルと、リン酸、クエン酸、又は乳酸を含有する原液と噴射剤を混合して、エアゾール剤を製造したところ、意外にも、低温保管時にエアゾール剤中で析出物が生じる場合があることが分かった。 In order to provide a minoxidil-containing aerosol agent that does not cause crystal precipitation even at a low temperature, the present inventors prepare a minoxidil-containing liquid agent that does not cause crystal precipitation at a low temperature, use this as a stock solution, and add a propellant to the aerosol agent. I tried to manufacture it. More specifically, when minoxidil was mixed with a stock solution containing phosphoric acid, citric acid, or lactic acid and a propellant to produce an aerosol agent, surprisingly, precipitates were formed in the aerosol agent during low temperature storage. It turns out that there are cases.
よって、本発明は、ミノキシジルを含有したエアゾール剤において、低温保管時に結晶が析出しないエアゾール剤を提供することを課題とする。 Therefore, it is an object of the present invention to provide an aerosol agent containing minoxidil in which crystals do not precipitate when stored at a low temperature.
本発明者らは、上記課題を解決すべく鋭意検討を重ねた結果、意外にも、原液中にクエン酸、リン酸、及び乳酸からなる群から選択される2種以上の酸を配合し、噴射剤としてジメチルエーテルを用いたエアゾール剤は、低温保管時に結晶が析出せず、ミノキシジルを溶解状態で含有できることを見出し、本発明を完成するに至った。 As a result of diligent studies to solve the above problems, the present inventors unexpectedly blended two or more kinds of acids selected from the group consisting of citric acid, phosphoric acid, and lactic acid in the undiluted solution. It has been found that an aerosol agent using dimethyl ether as a propellant does not precipitate crystals when stored at a low temperature and can contain minoxidyl in a dissolved state, and has completed the present invention.
すなわち本発明は、
(1)(a)ミノキシジル、並びに、リン酸、クエン酸、及び乳酸からなる群から選ばれる2種以上の酸を含む原液と、(b)ジメチルエーテルを含む噴射剤からなるエアゾール剤、
(2)原液中のミノキシジルの含有量が5w/v%以上である、(1)に記載のエアゾール剤、
である。
That is, the present invention
(1) (a) A stock solution containing minoxidil and two or more acids selected from the group consisting of phosphoric acid, citric acid, and lactic acid, and (b) an aerosol agent consisting of a propellant containing dimethyl ether.
(2) The aerosol agent according to (1), wherein the content of minoxidil in the stock solution is 5 w / v% or more.
Is.
本発明により、ミノキシジルを含有したエアゾール剤において、低温保管時に結晶が析出せず、ミノキシジルを溶解状態で含有したエアゾール剤を提供することが可能となった。また、原液と噴射剤の相溶性に優れたエアゾール剤となった。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an aerosol agent containing minoxidil in a dissolved state in which crystals do not precipitate during storage at a low temperature. In addition, it became an aerosol agent having excellent compatibility between the undiluted solution and the propellant.
本発明のエアゾール剤は、(a)ミノキシジル、並びに、リン酸、クエン酸、及び乳酸からなる群から選ばれる2種以上の酸を含む原液と、(b)ジメチルエーテルを含む噴射剤とから構成される。本発明のエアゾール剤は、低温保管時に結晶が析出せず、ミノキシジルを溶解状態で含有したエアゾール剤となる。
本発明のエアゾール剤を構成する原液は、ミノキシジル及び、リン酸、クエン酸、及び乳酸からなる群から選ばれる2種以上の酸を必須成分とし、必要に応じてアルコール類、水、その他一般の外用剤に用いられる種々の活性成分や補助成分を配合することができる。
The aerosol agent of the present invention is composed of (a) minoxidil, a stock solution containing two or more acids selected from the group consisting of phosphoric acid, citric acid, and lactic acid, and (b) a propellant containing dimethyl ether. To. The aerosol agent of the present invention is an aerosol agent containing minoxidil in a dissolved state without crystals precipitating during storage at a low temperature.
The undiluted solution constituting the aerosol agent of the present invention contains minoxidil and two or more kinds of acids selected from the group consisting of phosphoric acid, citric acid, and lactic acid as essential components, and if necessary, alcohols, water, and other general solutions. Various active ingredients and auxiliary ingredients used in external preparations can be blended.
本発明の原液中のミノキシジルは、通常医薬品に用いられる品質のものを適宜使用することができる。原液中のミノキシジルの含有量が多くなるにつれ低温での析出の課題が大きくなるため、ミノキシジルの濃度が高いほど、本発明を実施する意義が大きい。具体的には、原液中におけるミノキシジルの濃度は3w/v%以上が好ましく、より好ましくは5w/v%以上である。また上限は10w/v%が好ましい。 As the minoxidil in the undiluted solution of the present invention, those of the quality usually used for pharmaceutical products can be appropriately used. As the content of minoxidil in the undiluted solution increases, the problem of precipitation at low temperature increases. Therefore, the higher the concentration of minoxidil, the greater the significance of carrying out the present invention. Specifically, the concentration of minoxidil in the stock solution is preferably 3 w / v% or more, more preferably 5 w / v% or more. The upper limit is preferably 10 w / v%.
本発明の原液中には、リン酸、クエン酸及び乳酸からなる群から選ばれる2種以上の酸の配合が必須である。これらのうち1種類の酸だけでエアゾール剤を製造すると、低温保管時に結晶が析出し、ミノキシジルを溶解状態で含有させることができない。本発明の原液中におけるリン酸とクエン酸の配合比率は、リン酸1質量部に対してクエン酸0.3〜5質量部が好ましく、0.5〜2質量部がより好ましい。リン酸及びクエン酸の合計量は、0.1〜2.0w/v%が好ましく、0.3〜1.2w/v%がより好ましく、0.5〜1.0w/v%がさらに好ましい。また、リン酸と乳酸の配合比率は、リン酸1質量部に対して乳酸0.3〜5質量部が好ましく、0.5〜2質量部がより好ましい。リン酸と乳酸の合計量は、0.1〜2.0w/v%が好ましく、0.3〜1.2w/v%がより好ましく、0.5〜1.0w/v%がさらに好ましい。また、クエン酸と乳酸の配合比率は、クエン酸1質量部に対して乳酸0.3〜5質量部が好ましく、0.5〜2質量部がより好ましい。クエン酸及び乳酸の合計量は、0.1〜2.0w/v%が好ましく、0.3〜1.2w/v%がより好ましく、0.5〜1.0w/v%がさらに好ましい。 In the stock solution of the present invention, it is essential to mix two or more kinds of acids selected from the group consisting of phosphoric acid, citric acid and lactic acid. When an aerosol agent is produced using only one of these acids, crystals are precipitated during storage at a low temperature, and minoxidil cannot be contained in a dissolved state. The blending ratio of phosphoric acid and citric acid in the stock solution of the present invention is preferably 0.3 to 5 parts by mass, more preferably 0.5 to 2 parts by mass with respect to 1 part by mass of phosphoric acid. The total amount of phosphoric acid and citric acid is preferably 0.1 to 2.0 w / v%, more preferably 0.3 to 1.2 w / v%, still more preferably 0.5 to 1.0 w / v%. .. The blending ratio of phosphoric acid and lactic acid is preferably 0.3 to 5 parts by mass, more preferably 0.5 to 2 parts by mass, based on 1 part by mass of phosphoric acid. The total amount of phosphoric acid and lactic acid is preferably 0.1 to 2.0 w / v%, more preferably 0.3 to 1.2 w / v%, and even more preferably 0.5 to 1.0 w / v%. The mixing ratio of citric acid and lactic acid is preferably 0.3 to 5 parts by mass, more preferably 0.5 to 2 parts by mass, based on 1 part by mass of citric acid. The total amount of citric acid and lactic acid is preferably 0.1 to 2.0 w / v%, more preferably 0.3 to 1.2 w / v%, and even more preferably 0.5 to 1.0 w / v%.
また、原液のpHは、ミノキシジルの安定性、使用時の肌への刺激感、薬物の浸透性、使用感等の点から、4.0〜8.0の範囲に調整することが好ましく、5.0〜7.0の範囲が更に好ましい。 The pH of the undiluted solution is preferably adjusted to the range of 4.0 to 8.0 from the viewpoints of stability of minoxidil, irritation to the skin during use, drug permeability, feeling of use and the like. A range of .0 to 7.0 is more preferred.
本発明の原液には、使用感、ミノキシジルの溶解性及び安定性の点から、アルコール類と水との混合物を配合するのが好ましい。アルコール類の配合量は、原液全体の30〜80w/v%であることが好ましい。アルコール類としては、低級アルコール及び多価アルコールを単独又は組み合わせて使用することができる。低級アルコールとしては、炭素数1〜5のものが好ましく、例えばエタノールやイソプロパノールなどが好ましく、これらを組み合わせて使用することができる。低級アルコールの配合量は、原液全体の30w/v%以上が好ましく、更に好ましくは40w/v%以上である。多価アルコールとしては、1,3−ブチレングリコール、ジプロピレングリコール、プロピレングリコール、グリセリン等が挙げられ、これらを1種又は2種以上組み合わせて使用することができる。多価アルコールの配合量は、原液全体の30w/v%以下が好ましい。また、本発明の原液中の水の配合量は、特に制限はないが、原液全体に対して10〜50w/v%が好ましく、10〜30w/v%がより好ましく、10w/v%以上20w/v%未満がさらに好ましい。水の含有量は、配合した水の量及び配合した成分中の水分量から計算によって算出することもできるが、例えばカールフィッシャー水分計で測定することもできる。 The stock solution of the present invention preferably contains a mixture of alcohols and water from the viewpoint of usability, solubility of minoxidil and stability. The blending amount of alcohols is preferably 30 to 80 w / v% of the total stock solution. As the alcohols, lower alcohols and polyhydric alcohols can be used alone or in combination. As the lower alcohol, those having 1 to 5 carbon atoms are preferable, and for example, ethanol and isopropanol are preferable, and these can be used in combination. The blending amount of the lower alcohol is preferably 30 w / v% or more, more preferably 40 w / v% or more of the whole stock solution. Examples of the polyhydric alcohol include 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin and the like, and these can be used alone or in combination of two or more. The blending amount of the polyhydric alcohol is preferably 30 w / v% or less of the total stock solution. The amount of water blended in the undiluted solution of the present invention is not particularly limited, but is preferably 10 to 50 w / v%, more preferably 10 to 30 w / v%, and 10 w / v% or more and 20 w with respect to the entire undiluted solution. Less than / v% is more preferred. The water content can be calculated from the amount of mixed water and the amount of water in the mixed components, but it can also be measured by, for example, a Karl Fischer titer.
本発明のミノキシジルを含む原液には、上記した成分の他、本発明の効果を損なわない範囲で、一般の外用剤に用いられる種々の活性成分や補助成分を配合することができる。例えば、賦形剤、育毛成分(6−ベンジルアミノプリン、アデノシン、ペンタデカン酸グリセリド、何首鳥等)、血管拡張剤(塩化カルプロニウム、ニコチン酸ベンジル、センブリ抽出液、オタネニンジンエキス、チクセツニンジンチンキ、トウガラシチンキ等)、抗ヒスタミン剤(塩酸イソチペンジル、塩酸ジフェンヒドラミン等)、抗炎症剤(グアイアズレン、グリチルレチン酸等)、角質溶解剤(尿素、サリチル酸等)、殺菌剤(グルコン酸クロルヘキシジン、イソプロピルメチルフェノール、第4級アンモニウム塩、ピロクトンオラミン、ヒノキチオール等)、保湿剤(ヒアルロン酸又はその塩、コンドロイチン硫酸等)、各種動植物(イチイ、ボタンピ、カンゾウ、オトギリソウ、附子、ビワ、カワラヨモギ、コンフリー、アシタバ、サフラン、サンシシ、ローズマリー、セージ、モッコウ、セイモッコウ、ホップ、プラセンタ、ノコギリヤシ、パンプキンシード等)の抽出物、ビタミン類(酢酸トコフェロール、パントテニルエチルエーテル、パンテノール、塩酸ピリドキシン、酢酸レチノール、アスコルビン酸、硝酸チアミン、シアノコバラミン、ビオチン等)、抗酸化剤(ジブチルヒドロキシトルエン、ピロ亜硫酸ナトリウム、トコフェロール、エデト酸ナトリウム、アスコルビン酸、イソプロピルガレート等)、溶解補助剤(アジピン酸ジイソプロピル、ミリスチン酸イソプロピル、各種植物油、各種動物油、アルキルグリセリルエーテル、炭化水素類等)、代謝賦活剤、ゲル化剤(水溶性高分子等)、粘着剤、香料、清涼化剤(メントール、ハッカ油、カンフル等)、染料等の通常使用される成分を配合することができる。 In addition to the above-mentioned components, various active ingredients and auxiliary components used in general external preparations can be added to the stock solution containing minoxidil of the present invention as long as the effects of the present invention are not impaired. For example, hydrochloric acid, hair-growth component (6-benzylaminopurine, adenosine, pentadecanoic acid glyceride, ascorbic acid, etc.), vasodilator (carpronium chloride, benzyl nicotinate, assembly extract, otane carrot extract, chixetsu carrot tincture, etc. Togarashi tinki, etc.), antihistamines (isotipendyl hydrochloride, diphenhydramine hydrochloride, etc.), anti-inflammatory agents (guaizulene, glycyrrhetinic acid, etc.), keratolytic agents (urea, salicylic acid, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, quaternary grade 4) Ammonium salt, pyrocton olamine, hinokithiol, etc.), moisturizer (hyaluronic acid or its salt, chondroitin sulfate, etc.), various animals and plants (ichii, buttonpi, kanzo, otogirisou, tsuko, biwa, kawarayomogi, confrey, ascorbic acid, saffron, etc. Extracts of sanshishi, rosemary, sage, mokko, seimokko, hops, placenta, sawtooth palm, pumpkin seed, etc., vitamins (tocopherol acetate, pantothenyl ethyl ether, pantenol, pyridoxin hydrochloride, retinol acetate, ascorbic acid, thiamine nitrate , Cyanocobalamine, biotin, etc.), Antioxidants (dibutylhydroxytoluene, sodium pyrosulfate, tocopherol, sodium edetate, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils) , Alkyl glyceryl ether, hydrochloric acid, etc.), Metabolism activator, gelling agent (water-soluble polymer, etc.), adhesive, fragrance, cooling agent (menthol, peppermint oil, camphor, etc.), dye, etc. Ingredients can be blended.
本発明を構成する噴射剤としては、ジメチルエーテルを使用することが必須である。原液との相溶性が優れたものとなり、また、安定性及び使用感も良好となるからである。原液とジメチルエーテルの配合比率は原液1容量部に対してジメチルエーテル0.25〜1容量部が好ましい。0.25容量部を下回ると冷感が得られなくなり、1容量部を上回ると使用時の噴射剤臭が強く、良好な使用感が損なわれるためである。また、安定性、使用感を損なわない範囲でジメチルエーテルとともに他の圧縮ガス等の噴射剤を使用することができる。圧縮ガスとしては、炭酸ガス、窒素、亜酸化窒素等が挙げられる。 It is essential to use dimethyl ether as the propellant constituting the present invention. This is because the compatibility with the undiluted solution is excellent, and the stability and usability are also good. The mixing ratio of the undiluted solution and dimethyl ether is preferably 0.25 to 1 part by volume of dimethyl ether with respect to 1 part by volume of the undiluted solution. This is because if it is less than 0.25 parts by volume, a cold feeling cannot be obtained, and if it exceeds 1 part by volume, the propellant odor during use is strong and a good feeling of use is impaired. Further, other propellants such as compressed gas can be used together with dimethyl ether as long as the stability and usability are not impaired. Examples of the compressed gas include carbon dioxide gas, nitrogen, nitrous oxide and the like.
本発明のエアゾール剤を充填する容器は、エアゾールの内圧に耐える耐圧性と、内容物が洩れない気密性を有していることが必要である。法規で規定される耐圧性能(1.3MPaで変形せず、1.5MPaで破壊されないこと)が維持されていれば、素材は、アルミニウム、ガラス、ブリキ、合成樹脂のいずれであってもよい。ブリキ容器、アルミニウム容器を用いる場合には、腐食防止のために樹脂による表面コートを行うことができるが、汎用性の観点からアルミニウム容器が好ましい。また、本発明のエアゾール剤に用いる容器は、耐圧容器の他、バルブ、ボタン、スパウト、キャップ等が、公知のエアゾール容器と同様に備わっている。 The container filled with the aerosol agent of the present invention is required to have a pressure resistance to withstand the internal pressure of the aerosol and an airtightness to prevent the contents from leaking. The material may be aluminum, glass, tinplate, or synthetic resin as long as the pressure resistance performance specified by law (not deformed at 1.3 MPa and not destroyed at 1.5 MPa) is maintained. When a tin container or an aluminum container is used, the surface can be coated with a resin to prevent corrosion, but the aluminum container is preferable from the viewpoint of versatility. Further, the container used for the aerosol agent of the present invention is provided with a valve, a button, a spout, a cap and the like in addition to a pressure-resistant container in the same manner as a known aerosol container.
本発明のエアゾール剤は、常法に従い、上記各成分を含有することにより調製される。 The aerosol agent of the present invention is prepared by containing each of the above components according to a conventional method.
以下に、実施例、比較例及び試験例を記載し、本発明をさらに具体的に説明するが、本発明はこれら実施例等により何ら制約されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples, but the present invention is not limited to these Examples and the like.
下記の原液1〜5を調製した。なお、エタノールは95%エタノールを使用した。 The following stock solutions 1 to 5 were prepared. As ethanol, 95% ethanol was used.
※原液1
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、クエン酸0.45g、リン酸0.38g、精製水で全量を100mLとし、撹拌溶解してpH6.1の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 1
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, citric acid 0.45 g, phosphoric acid 0.38 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.1. The content of water in the undiluted solution was 17 g / 100 mL.
※原液2
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、クエン酸0.55g、リン酸0.34g、精製水で全量を100mLとし、撹拌溶解してpH6.1の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 2
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, citric acid 0.55 g, phosphoric acid 0.34 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.1. The content of water in the undiluted solution was 17 g / 100 mL.
※原液3
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、リン酸0.4g、乳酸0.4g、精製水で全量を100mLとし、撹拌溶解してpH6.1の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 3
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, phosphoric acid 0.4 g, lactic acid 0.4 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.1. The content of water in the undiluted solution was 17 g / 100 mL.
※原液4
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、クエン酸0.45g、乳酸0.5g、精製水で全量を100mLとし、撹拌溶解してpH6.0の原液を得た。なお、原液中の水の含量は、16g/100mLであった。
* Undiluted solution 4
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, citric acid 0.45 g, lactic acid 0.5 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.0. The content of water in the undiluted solution was 16 g / 100 mL.
※原液5
ミノキシジル5g、1,3−ブチレングリコール12g、エタノール60g、クエン酸0.45g、乳酸0.5g、精製水で全量を100mLとし、撹拌溶解してpH6.0の原液を得た。なお、原液中の水の含量は、14g/100mLであった。
* Undiluted solution 5
Minoxidil 5 g, 1,3-butylene glycol 12 g, ethanol 60 g, citric acid 0.45 g, lactic acid 0.5 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.0. The content of water in the undiluted solution was 14 g / 100 mL.
※原液6
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、リン酸0.38g、精製水で全量を100mLとし、撹拌溶解してpH6.5の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 6
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, phosphoric acid 0.38 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.5. The content of water in the undiluted solution was 17 g / 100 mL.
※原液7
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、クエン酸0.45g、精製水で全量を100mLとし、撹拌溶解してpH6.5の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 7
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, citric acid 0.45 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.5. The content of water in the undiluted solution was 17 g / 100 mL.
※原液8
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、リン酸1.02g、精製水で全量を100mLとし、撹拌溶解してpH6.0の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 8
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, phosphoric acid 1.02 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.0. The content of water in the undiluted solution was 17 g / 100 mL.
※原液9
ミノキシジル5g、1,3−ブチレングリコール10g、エタノール60g、乳酸0.5g、精製水で全量を100mLとし、撹拌溶解してpH6.4の原液を得た。なお、原液中の水の含量は、17g/100mLであった。
* Undiluted solution 9
Minoxidil 5 g, 1,3-butylene glycol 10 g, ethanol 60 g, lactic acid 0.5 g, purified water to make a total volume of 100 mL, and the mixture was stirred and dissolved to obtain a stock solution having a pH of 6.4. The content of water in the undiluted solution was 17 g / 100 mL.
原液1〜9の処方を表1に示す(なお、表中の単位はg/100mLである。) The formulations of undiluted solutions 1 to 9 are shown in Table 1 (note that the unit in the table is g / 100 mL).
<試験例1:原液の低温安定性試験>
原液1〜9をそれぞれ透明容器に充填し、5℃で9日間保管後の結晶析出の有無を目視で評価した。その結果、結晶析出は生じなかった。
<Test Example 1: Low temperature stability test of stock solution>
The stock solutions 1 to 9 were each filled in a transparent container, and the presence or absence of crystal precipitation after storage at 5 ° C. for 9 days was visually evaluated. As a result, no crystal precipitation occurred.
(実施例1)
原液1のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルとの容積比が1/0.5になるように13.3mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 1)
26.7 mL of the stock solution 1 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the propellant dimethyl ether becomes 1 / 0.5. Got
(実施例2)
原液1のうち32.0mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.25になるように8.0mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 2)
32.0 mL of the stock solution 1 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 8.0 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and dimethyl ether, which is the propellant, is 1 / 0.25, and the aerosol agent is added. Obtained.
(実施例3)
原液2のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように13.3mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 3)
26.7 mL of the stock solution 2 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the propellant dimethyl ether becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(実施例4)
原液3のうち30.0mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように15.0mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 4)
30.0 mL of the undiluted solution 3 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 15.0 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and dimethyl ether, which is the propellant, becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(実施例5)
原液4のうち30.0mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように15.0mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 5)
30.0 mL of the undiluted solution 4 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 15.0 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and dimethyl ether, which is the propellant, becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(実施例6)
原液5のうち30.0mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように15.0mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Example 6)
30.0 mL of the stock solution 5 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 15.0 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and dimethyl ether, which is the propellant, becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(比較例1)
原液6のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように13.3mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Comparative Example 1)
26.7 mL of the undiluted solution 6 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the propellant dimethyl ether becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(比較例2)
原液7のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように13.3mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Comparative Example 2)
26.7 mL of the undiluted solution 7 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the propellant dimethyl ether becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(比較例3)
原液8のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように13.3mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Comparative Example 3)
26.7 mL of the undiluted solution 8 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the propellant dimethyl ether becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(比較例4)
原液9のうち30.0mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤であるジメチルエーテルを容積比が1/0.5になるように15.0mLのジメチルエーテルを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Comparative Example 4)
30.0 mL of the undiluted solution 9 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 15.0 mL of dimethyl ether is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and dimethyl ether, which is the propellant, becomes 1 / 0.5, and the aerosol agent is added. Obtained.
(比較例5)
原液1のうち26.7mLを透明ガラス耐圧瓶に充填した。次に、透明ガラス耐圧瓶にエアゾールバルブを取りつけ、原液と噴射剤である液化石油ガスを容積比が1/0.5になるように13.3mLの液化石油ガスを透明ガラス耐圧瓶に充填し、エアゾール剤を得た。
(Comparative Example 5)
26.7 mL of the stock solution 1 was filled in a transparent glass pressure resistant bottle. Next, an aerosol valve is attached to the transparent glass pressure-resistant bottle, and 13.3 mL of liquefied petroleum gas is filled in the transparent glass pressure-resistant bottle so that the volume ratio of the undiluted solution and the liquefied petroleum gas that is the propellant is 1 / 0.5. , Obtained an aerosol agent.
実施例1〜実施例6、比較例1〜比較例5の原液と噴射剤を表2に示す(なお、表中のDMEはジメチルエーテルの略であり、LPGは液化石油ガスの略である。) Table 2 shows the stock solutions and propellants of Examples 1 to 6 and Comparative Examples 1 to 5 (DME in the table is an abbreviation for dimethyl ether, and LPG is an abbreviation for liquefied petroleum gas).
<試験例2:相溶性、低温安定性の評価>
実施例1〜実施例6及び比較例1〜比較例5に関し、調製直後の相溶性及び5℃で9日間保管後の結晶析出の有無を評価した。調製直後の相溶性は、原液と噴射剤が混和した場合を○、原液と噴射剤が分離したものを×と表記した。低温安定性の評価は、結晶が析出せず混和したままであったものを○、結晶が析出したものを×と表記した。結果を表3に示す。
<Test Example 2: Evaluation of compatibility and low temperature stability>
With respect to Examples 1 to 6 and Comparative Examples 1 to 5, the compatibility immediately after preparation and the presence or absence of crystal precipitation after storage at 5 ° C. for 9 days were evaluated. The compatibility immediately after preparation is indicated by ◯ when the undiluted solution and the propellant are mixed, and × when the undiluted solution and the propellant are separated. In the evaluation of low temperature stability, those in which crystals did not precipitate and remained mixed were marked with ◯, and those in which crystals were precipitated were marked with x. The results are shown in Table 3.
試験例1から明らかなように、クエン酸、リン酸、または乳酸を単独使用した原液6〜9については、いずれも5℃で9日間保管したときに、結晶析出等の問題はなかった。しかし、噴射剤としてジメチルエーテルを用いてエアゾール剤とすると、低温保管時に結晶が析出した(比較例1〜4)。一方、本発明の、原液中にクエン酸、リン酸及び乳酸から選ばれる2種以上の酸を併用した実施例1〜6は、噴射剤としてジメチルエーテルを用いたエアゾール剤を調製しても低温保管時に結晶析出を生じなかった。また、比較例5に示すように、噴射剤として液化石油ガスを用いた場合、調製直後から原液と噴射剤が分離し、均一にならなかった。計量性が求められずミノキシジル含有エアゾール剤としては、適さないという結果となった。 As is clear from Test Example 1, all of the stock solutions 6 to 9 using citric acid, phosphoric acid, or lactic acid alone did not have any problems such as crystal precipitation when stored at 5 ° C. for 9 days. However, when dimethyl ether was used as the propellant to prepare an aerosol agent, crystals were precipitated during storage at a low temperature (Comparative Examples 1 to 4). On the other hand, in Examples 1 to 6 of the present invention in which two or more acids selected from citric acid, phosphoric acid and lactic acid are used in combination in the undiluted solution, even if an aerosol agent using dimethyl ether as a propellant is prepared, it is stored at a low temperature. Occasionally no crystal precipitation occurred. Further, as shown in Comparative Example 5, when liquefied petroleum gas was used as the propellant, the stock solution and the propellant were separated immediately after the preparation and were not uniform. The result was that it was not suitable as a minoxidil-containing aerosol agent because it was not required to be measurable.
本発明により、ミノキシジルを含有したエアゾール剤において、低温保管時に結晶が析出せず、ミノキシジルを溶解状態で含有したエアゾール剤を提供することが可能になった。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an aerosol agent containing minoxidil in a dissolved state in which crystals do not precipitate during storage at a low temperature.
Claims (2)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016067443 | 2016-03-30 | ||
JP2016067443 | 2016-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017186310A JP2017186310A (en) | 2017-10-12 |
JP6880871B2 true JP6880871B2 (en) | 2021-06-02 |
Family
ID=60046082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017052720A Active JP6880871B2 (en) | 2016-03-30 | 2017-03-17 | Aerosol agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6880871B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7124435B2 (en) * | 2017-05-18 | 2022-08-24 | 大正製薬株式会社 | external composition |
BR102021003531A2 (en) * | 2021-02-24 | 2022-08-30 | Eurofarma Laboratorios S.A. | FOAMBLE TOPICAL PHARMACEUTICAL COMPOSITION |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1112136A (en) * | 1997-06-27 | 1999-01-19 | Taisho Pharmaceut Co Ltd | Minoxidil-formulated aerosol |
CN100361644C (en) * | 2000-04-07 | 2008-01-16 | 大正制药株式会社 | Hair growth stimulant compositions |
WO2014122436A1 (en) * | 2013-02-07 | 2014-08-14 | Cipla House | Topical pharmaceutical compositions comprising minoxidil |
US9675537B2 (en) * | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
-
2017
- 2017-03-17 JP JP2017052720A patent/JP6880871B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017186310A (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5561264B2 (en) | Hair growth composition | |
JP7099581B2 (en) | External composition | |
JP6819275B2 (en) | Topical solution | |
JP2021028345A (en) | Composition for external use | |
WO2014017573A1 (en) | Composition for agent for external use | |
JP6880871B2 (en) | Aerosol agent | |
JP2023169290A (en) | External composition containing minoxidil, and method for preventing deposition of minoxidil | |
JP2023099672A (en) | External pharmaceutical composition | |
JP6848565B2 (en) | Aerosol agent | |
JP6221536B2 (en) | Composition for external use | |
JP6424815B2 (en) | Composition for external use | |
JP6825354B2 (en) | Topical composition | |
JP2015187094A (en) | external composition | |
JP5286999B2 (en) | Minoxidil-containing liquid | |
JP5881879B1 (en) | External composition for improving acne vulgaris | |
JP2021165305A (en) | Composition for external use | |
JP2023044651A (en) | aerosol agent | |
JP2023044652A (en) | external composition | |
JP2022106292A (en) | Aerosol agent | |
JP2020172482A (en) | External pharmaceutical composition | |
JP5433142B2 (en) | Aerosol | |
JP2021123587A (en) | Pharmaceutical composition for external use | |
JP2021167298A (en) | Pharmaceutical composition for external use | |
JP2021123585A (en) | Pharmaceutical preparation for external use | |
JP2021123586A (en) | Pharmaceutical composition for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210406 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6880871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |